Cargando…
异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析
OBJECTIVE: To analyze the clinical characteristics and outcomes of non-aspergillus molds infection (NAMI) patients who underwent allogeneic stem cell transplantation. METHODS: Total 24 patients diagnosed as proven or probable non-aspergillus molds infection after allo-HSCT at the Peking University I...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525166/ https://www.ncbi.nlm.nih.gov/pubmed/32942814 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.08.002 |
_version_ | 1783588687830843392 |
---|---|
collection | PubMed |
description | OBJECTIVE: To analyze the clinical characteristics and outcomes of non-aspergillus molds infection (NAMI) patients who underwent allogeneic stem cell transplantation. METHODS: Total 24 patients diagnosed as proven or probable non-aspergillus molds infection after allo-HSCT at the Peking University Institute of Hematology from January 2010 to December 2016 were retrospectively reviewed. RESULTS: Among the 24 non-aspergillus molds infection patients, 22 (91.6%) underwent haploidentical stem cell transplantation, while 1 (4.2%) underwent matched-sibling donor transplantation, and 1 (4.2%) underwent HLA-matched unrelated donor transplantation. Ten (41.7%) patients were diagnosed as proven NAMI, and 14 (58.3%) were probable NAMI. The median time to NAMI diagnosis was 188 (2–856) d after transplantation. Five (20.8%) patients had Mucorales infection, 14 (58.3%) Rhizopus infection, 3 (12.5%) had Absidia orchidis infection, and 2 (8.3%) had Scedosporium apiospermum infection. The response rate at was 38.9% (7/18) in 18 patients who adjusted antifungal therapy based on the etiology. After a median 229 (2–2280) days follow-up after diagnosis, the 2-year overall survival was (24.0±14.5) %. CONCLUSION: The major pathogen of NAMI after allo-HSCT was Rhizopus, and the mortality of NAMI after allo-HSCT was very high due to lack of early effective therapy. |
format | Online Article Text |
id | pubmed-7525166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-75251662020-09-30 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the clinical characteristics and outcomes of non-aspergillus molds infection (NAMI) patients who underwent allogeneic stem cell transplantation. METHODS: Total 24 patients diagnosed as proven or probable non-aspergillus molds infection after allo-HSCT at the Peking University Institute of Hematology from January 2010 to December 2016 were retrospectively reviewed. RESULTS: Among the 24 non-aspergillus molds infection patients, 22 (91.6%) underwent haploidentical stem cell transplantation, while 1 (4.2%) underwent matched-sibling donor transplantation, and 1 (4.2%) underwent HLA-matched unrelated donor transplantation. Ten (41.7%) patients were diagnosed as proven NAMI, and 14 (58.3%) were probable NAMI. The median time to NAMI diagnosis was 188 (2–856) d after transplantation. Five (20.8%) patients had Mucorales infection, 14 (58.3%) Rhizopus infection, 3 (12.5%) had Absidia orchidis infection, and 2 (8.3%) had Scedosporium apiospermum infection. The response rate at was 38.9% (7/18) in 18 patients who adjusted antifungal therapy based on the etiology. After a median 229 (2–2280) days follow-up after diagnosis, the 2-year overall survival was (24.0±14.5) %. CONCLUSION: The major pathogen of NAMI after allo-HSCT was Rhizopus, and the mortality of NAMI after allo-HSCT was very high due to lack of early effective therapy. Editorial office of Chinese Journal of Hematology 2020-08 /pmc/articles/PMC7525166/ /pubmed/32942814 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.08.002 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title_full | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title_fullStr | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title_full_unstemmed | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title_short | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
title_sort | 异基因造血干细胞移植后非曲霉属丝状真菌病24例临床分析 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525166/ https://www.ncbi.nlm.nih.gov/pubmed/32942814 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.08.002 |
work_keys_str_mv | AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī AT yìjīyīnzàoxuègànxìbāoyízhíhòufēiqūméishǔsīzhuàngzhēnjūnbìng24lìlínchuángfēnxī |